Mirae Asset Global Investments Co. Ltd. grew its holdings in Mylan NV (NASDAQ:MYL) by 38.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 119,535 shares of the company’s stock after buying an additional 33,178 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Mylan were worth $4,384,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of MYL. Cornerstone Wealth Management LLC purchased a new stake in shares of Mylan in the second quarter valued at approximately $306,000. Jennison Associates LLC increased its position in shares of Mylan by 16.2% during the second quarter. Jennison Associates LLC now owns 1,667,552 shares of the company’s stock worth $60,265,000 after purchasing an additional 232,483 shares in the last quarter. Barings LLC increased its position in shares of Mylan by 11.3% during the second quarter. Barings LLC now owns 66,601 shares of the company’s stock worth $2,406,000 after purchasing an additional 6,769 shares in the last quarter. LMR Partners LLP purchased a new stake in shares of Mylan during the second quarter worth approximately $250,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in shares of Mylan during the second quarter worth approximately $1,950,000. Institutional investors and hedge funds own 82.17% of the company’s stock.
Shares of NASDAQ:MYL opened at $30.55 on Friday. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.26 and a quick ratio of 0.77. The firm has a market capitalization of $16.42 billion, a price-to-earnings ratio of 6.70, a P/E/G ratio of 1.05 and a beta of 1.49. Mylan NV has a 52-week low of $30.33 and a 52-week high of $47.82.
Several brokerages recently commented on MYL. Wells Fargo & Co reiterated a “hold” rating on shares of Mylan in a research report on Wednesday, August 15th. ValuEngine cut Mylan from a “hold” rating to a “sell” rating in a research report on Tuesday, September 11th. Evercore ISI upgraded Mylan from an “in-line” rating to an “outperform” rating in a research report on Friday, August 24th. BidaskClub cut Mylan from a “sell” rating to a “strong sell” rating in a research report on Tuesday, October 9th. Finally, Cowen set a $31.00 price target on Mylan and gave the stock a “hold” rating in a research report on Tuesday, November 6th. Two analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $46.56.
TRADEMARK VIOLATION NOTICE: This story was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.chaffeybreeze.com/2018/12/08/mylan-nv-myl-stake-increased-by-mirae-asset-global-investments-co-ltd.html.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Read More: How analysts view the yield curve
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.